Congratulations to Ms Mariana Bertoncelli Tanaka, appointed Consultant Urological Surgeon in Robotic Prostatectomy & Focal Therapy 👏 First female robotic prostatectomy surgeon in London & first female dual-accredited robotic + focal therapy surgeon in the UK! @imperialurology

Great to see the @NICEComms re-review/approval of #abiraterone in #ProstateCancer . Demonstrating new process for re-reviewing negative @NICEComms decisions when medicines become #generic or #biosimilar @pash22 @CMO_England @ProstateUK @ProfKarolSikora https://t.co/74nrMYEYhk

Just published in @BMJOncology #openaccess led by @HealthCommunic2 and with @SirohiBhawna and other colleagues in India. Results from a qualitative study of Indian oncologists on their perceptions regarding FDA approval and different guidelines. 🧵 https://t.co/J82tXIgeaC

Proud of David for taking on such important work and spearheading this project! #ESMO25

Thankful to @myESMO for the opportunity to present our study with co-authors @kjmeetswrld @DrMarkLythgoe at #ESMO25 on the state of the global medical oncology workforce. We identified a total of 82,995 medical oncologists in practice across the globe. Disparities exist in

In the future, intravenous will no longer be manufactured and subcutaneous will be priced higher. Entry of biosimilar will be delayed. Cost of convenience. https://t.co/QPSz92JLCQ

We got a new paper for you for your weekend reading. In this new research article in collaboration with @CDNCancerTrials now published in @JNCI_Now , we show that among cancer patients participating in clinical trials 1. More than 1/3 patients have baseline financial difficulty

The march on #subcutaneous #immunotherapy continued with the @US_FDA approval of SC #pembrolizumab - will this significantly improve access or is it just patent evergreening? @oncology_bg @pash22 @tnewsomdavis @kjmeetswrld @SullivanProf @arkhaki https://t.co/rviIy07oco

Today @imperialcollege confers upon me the title of full Professor of Experimental Cancer Therapeutics & Medical Oncology. I owe this to more people I can count but dedicate it to my patients past and future, with the promise that enthusiasm to improve cancer care won’t stop here

Applications for the 2026 Common Sense Oncology Cancer Health Services Research Fellowship will close on Sept 18, 2025 at 4 pm EDT. If you are approaching completion of training in clinical or medical oncology, or have completed training within the last five years, this

Our new editorial just published in @BMJOncology led by @lateuwen where we discuss the use of inferior control arm in cancer drug trials run in LMICs. https://t.co/m1fwEkZu6N

Exciting to see the trial I wrote at @ASCO @AACR #VailWorkshop2019 published. Thanks to mentor @PGrivasMDPhD and for the team @fredhutch carrying this through to completion! #PDG6

#UK healthcare research is in serious decline in latest @nature rankings No institution in top 50 #globally or even top 25 in #Europe………….links to decline of #physican #Scientists https://t.co/DDFCsJ8ZJS @CRUK_Policy @UKRI_News @SullivanProf @bmj_latest @andrewgregory

>100000 single-arm trials exist. Most use convenience samples & give weak non-generalizable evidence. We can do better. We propose Random Invitation Single-Arm Trials (RISAT) - a simple way to get randomized real-world evidence from SATs. @AnnalsofIM https://t.co/K8lnp34t00

Massive congratulations our fantastic Clinical Research Fellow Dr James Clark on passing his PhD viva this afternoon!!! 🎉🎉🎉 Huge thank you to his lovely examiners Professors Gourley and Aboagye for an excellent discussion! @ImperialSandC @imperialcollege

🚨Our RWE #perioperative #NSCLC study now in @JAMANetworkOpen study of 1334 pts with stage II–IIIA resectable NSCLC: ◼️Neoadj DMFS @ 18 mo: 80% ◼️Adj DMFS @ 18 mo: 83 % ◼️Uptake was low: <30% ◼️Favorable outcomes, but time to expand access @OncoAlert https://t.co/sGLPCkGFPr

Simple things work best in #clinical #trial recruitment - single page recruitment letter………….though no preference in different colours! @pash22 @ECMC_UK @sarah_blagden https://t.co/GLKrdWJcJ1

Thank you @CancerTodayMag @AACR for featuring our recent @myESMO Real World Data & Digital Oncology study on the portrayal of cancer in public figures in news stories. The public should be cognizant that many news articles lack pertinent details on an individual's diagnosis,

@DrMarkLythgoe @DrSidMukherjee @NewYorker @NHSuk @SullivanProf @oncology_bg @EricTopol @sarah_blagden Yup, already tweeted that excellent @DrSidMukherjee article in @NewYorker earlier this morning @NHSEngland @naserturabi @paulpharoah

Excellent article 'The Catch in Catching Cancer Early' from @DrSidMukherjee in the @NewYorker discussing the promise of #early #cancer #detection and the experience with #GRAIL in @NHSuk @SullivanProf @oncology_bg @pash22 @EricTopol @sarah_blagden https://t.co/IbQ8r5Wy0E.